Year: 2020
Type: review
Abstract: Immune effector cell (IEC) therapy is emerging as a promising approach in the field of cancer immunotherapy. Clinical IEC trials, predominantly using chimeric antigen receptor (CAR) T cells, have shown excellent responses in CD19 + B cell malignancies and multiple myeloma. In solid tumors, preclinical data are encouraging, but clinical data are in their infancy, and there are challenges in using CAR T therapy in this setting, including (1) on-target off-tumor toxicity, (2) optimal target identification, (3) effective trafficking into bulky tumor tissue, and (4) resistance to tumor immune evasion mechanisms. Novel techniques and modifications are being explored in both the preclinical and clinical settings, aiming to improve treatment efficacy and address the aforementioned obstacles to successful CAR T therapy in solid tumors. Here we review these challenges in a clinically oriented approach and summarize published clinical trials using CAR T therapy in a variety of solid tumors.
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
Funders: Amgen, Bristol-Myers Squibb, American Physicians Fellowship for Medicine in Israel, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, American Society of Clinical Oncology, Ariad Pharmaceuticals, Celgene, Jazz Pharmaceuticals, Society for Immunotherapy of Cancer, Clovis Oncology, Incyte, MacroGenics, Daiichi-Sankyo, Eisai, Genentech, Kite Pharma, Pharmacyclics, Ignyta, National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W3040444874